Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

First Results Keep AstraZeneca’s Hopes High For Oral PCSK9 Inhibitor

May 29 2024

• By Andrew McConaghie

Astrazeneca

Related Content

AstraZeneca Targets $80bn Sales By 2030 But Analysts Still To Be Convinced

May 22 2024

NewAmsterdam Takes Another Step Toward CETP Inhibitor Success

Jan 17 2023

Merck & Co.’s Big Ambition To ‘Democratize’ PCSK9s

Mar 07 2023

Related Companies

AstraZeneca PLC

Merck & Co., Inc.

Amgen, Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Novartis AG

NewAmsterdam Pharma BV

Additional Topics

Clinical Trials Companies Research & Development Cardiovascular BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window